One of the biggest public growing threat is the rapid emergence of mosquito borne virus called as Zika virus. Zika virus was first identified in rhesus monkey in the year 1947 in Uganda. Later in 1952 the virus was identified in humans. The virus is a single-stranded RNA virus of the Flaviviridae family, and is transmitted by two species of Aedes genus, Aedes aegypti and Aedes albopictus. These are the same mosquito species that also spread dengue and chikungunya virus. The virus can also be vertically transmitted during fetal/perinatal period or by unprotected sexual contact. In case of perinatal transmission the virus can pass from mother to fetus through trans-placental transmission which can lead to the most common birth defect of brain called as microcephaly and other severe fetal brain defects. Eye defect, hearing problems and impaired growth are some of the issues commonly associated with the infection of Zika virus in fetus. Apart from this several evidences of Guillain-Barre syndrome, have also been reported in patients carrying the virus. Guillain-Barre syndrome is an uncommon sickness of the nervous system which leads to ascending paralysis. However, the risk is found to be higher in pregnant women’s during their first trimester of pregnancy period. Symptoms associated with the infection of Zika virus includes, fever, rashes, joint pain, conjunctivitis, muscle pain and headache. These symptoms last for several days to weeks. Africa, America, Asia and Pacific regions are likely to be dominated regions witnessing outbreaks of Zika virus.
The first largest outbreak of Zika virus was reported in the year 2007 across the Pacific island of Yap, in the Federated States of Micronesia. In 2016, World Health Organization (WHO) estimated the local transmission of Zika infection in more than 20 countries and territories across the Americas. Currently a number of Zika virus testing assays are available in the market some of which have received Emergency Use Authorization (EUA) while some of them are used for Research Use Only (RUO) and are used as Laboratory Developed Test (LDT). Currently, a number of diagnostic tests are available in the market for the diagnosis of Zika virus in humans. This includes, Zika ELITe MGB detection test, Sentosa SA ZIKV RT-PCR, LightMix Zika rRT-PCR test and many more. All these tests allow qualitative detection of RNA from Zika virus from body samples such as urine, human serum and plasma. The market for zika virus testing is expected to rise over the forecast period owing to continuous increase in population exhibiting symptoms of Zika virus over the forecast period.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2913
Zika Virus Testing Market: Drivers & Restraints
Expanded disease surveillance efforts undertaken by U.S. Food and Drug Administration (FDA) and U.S. Department of Health and Human Services (HHS) is expected to spur the market for Zika virus testing in the U.S. In august 2016, FDA announced screening of all donated blood and blood products for Zika virus across the world. This would help prevent increased chances of getting infected through transfusion-transmitted infections (TTIs). Substantial spending by U.S. government and FDA to add Zika screening program across all the hospitals and blood banks in U.S. is expected to spur the market for Zika virus testing over the forecast period. Furthermore, increasing efforts by various manufacturers to develop Zika virus screening tests is expected to accelerate the market growth in the coming years. Major demand for Zika virus testing is expected to come from Florida attributed to increasing number of patients exhibiting symptoms of Zika virus. Lack of awareness in the developing countries and inaccurate results from available diagnostic tests may affect the revenues for Zika virus testing market globally over the forecast period.
Zika Virus Testing Market: Segmentation
Zika virus testing market is segmented by test type, route of administration, end user and geography:
- By Test Type
- Nucleic Acid Amplification Test/ Molecular Tests
- Zika Virus Antibody Test/ Serological Test
- By End User
- Diagnostic Centers
- Pathology Clinics
Zika Virus Testing Market: Overview
According to WHO, since 2007, 67 countries and territories reported the evidence of Zika virus transmission. At present, the diagnosis of Zika virus in humans is dependent upon the molecular detection of viral RNA. However, presence of RNA only during the viraemia i.e. presence the virus in blood, and close clinical association of Zika symptoms with dengue and other infections, has resulted in lare number of undiagnosed cases.
Accessibility of better diagnostic testing services (i.e. rapid near-patient tests) across several haeltcare facilities is expected to fuel the market for Zika virus testing over the forecast period.
Zika Virus Testing Market: Region-wise Outlook
On the basis of region presence, Zika virus testing market is segmented into seven key regions: North America, Latin America, and Eastern Europe, Western Europe, and Asia pacific excluding japan, Japan, Middle East and Africa. Continuous spread of Zika virus across several countries in North America is expected to increase the demand for Zika virus testing services over the forecast period. WHO estimated that as of July 2016, in the U.S. CDC reported 12 birth defects related cases and six pregnancy losses. Furthermore, increasing efforts by HHS, Biomedical Advanced Research and Development Authority (BARDA) to raise the fund for development of diagnostic assays for Zika virus detection is expected to drive the market growth of Zika virus testing over the forecast period. Also the Zika virus outbreak in several Latin American countries is rapidly growing. For example in Brazil alone the virus is known to affect 21 states out of 26 states. Rapid local transmission of Zika virus across the globe is expected to result in more number of diagnostic assays performed thus driving the revenues.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-2913
Zika Virus Testing Market: Key Players
Some of the key market players in the Zika virus testing market are, ELITechGroup Inc. Molecular Diagnostics, Abbott Molecular Inc., ARUP Laboratories, Vela Diagnostics USA Inc., Roche Molecular Systems Inc., InBios International, Inc., Luminex Corporation, Siemens Healthcare Diagnostics Inc., Hologic, Inc. and Focus Diagnostics, Inc.
This post has been seen 558 times.